Cargando…

Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report

RATIONALE: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Abramavicius, Silvijus, Velickiene, Dzilda, Kadusevicius, Edmundas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626305/
https://www.ncbi.nlm.nih.gov/pubmed/28953662
http://dx.doi.org/10.1097/MD.0000000000008159
_version_ 1783268525022904320
author Abramavicius, Silvijus
Velickiene, Dzilda
Kadusevicius, Edmundas
author_facet Abramavicius, Silvijus
Velickiene, Dzilda
Kadusevicius, Edmundas
author_sort Abramavicius, Silvijus
collection PubMed
description RATIONALE: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxicity is suspected and intravenous methylprednisolone is co-administrated. PATIENT CONCERNS: A 74-year-old woman presented with spontaneous retro-bulbar pain, eyelid swelling and inconstant diplopia. DIAGNOSES: Thyrotoxicosis and severe GO with suspected optic nerve damage and drug induced liver injury (DILI). INTERVENTIONS: Intravenous methylprednisolone pulse therapy was administered to treat GO and methimazole was continued for thyrotoxicosis. Dose of methimazole was reduced after exclusion of concurrent infection and active liver disease. OUTCOMES: The GO symptoms (eyelid swelling, sight loss, proptosis, retro-bulbar pain, diplopia) markedly decreased after the treatment course. Liver transaminases spontaneously returned to normal ranges and remained normal during the next 12 months until the Graves’ disease until the treatment was completed. LESSONS: 1. The interaction of methimazole and methylprednisolone may result in DILI. 2. In a patient without concomitant liver diseases MP can be continued if the methimazole dose is reduced if no other treatment options are available.
format Online
Article
Text
id pubmed-5626305
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-56263052017-10-11 Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report Abramavicius, Silvijus Velickiene, Dzilda Kadusevicius, Edmundas Medicine (Baltimore) 4200 RATIONALE: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxicity is suspected and intravenous methylprednisolone is co-administrated. PATIENT CONCERNS: A 74-year-old woman presented with spontaneous retro-bulbar pain, eyelid swelling and inconstant diplopia. DIAGNOSES: Thyrotoxicosis and severe GO with suspected optic nerve damage and drug induced liver injury (DILI). INTERVENTIONS: Intravenous methylprednisolone pulse therapy was administered to treat GO and methimazole was continued for thyrotoxicosis. Dose of methimazole was reduced after exclusion of concurrent infection and active liver disease. OUTCOMES: The GO symptoms (eyelid swelling, sight loss, proptosis, retro-bulbar pain, diplopia) markedly decreased after the treatment course. Liver transaminases spontaneously returned to normal ranges and remained normal during the next 12 months until the Graves’ disease until the treatment was completed. LESSONS: 1. The interaction of methimazole and methylprednisolone may result in DILI. 2. In a patient without concomitant liver diseases MP can be continued if the methimazole dose is reduced if no other treatment options are available. Wolters Kluwer Health 2017-09-29 /pmc/articles/PMC5626305/ /pubmed/28953662 http://dx.doi.org/10.1097/MD.0000000000008159 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 4200
Abramavicius, Silvijus
Velickiene, Dzilda
Kadusevicius, Edmundas
Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
title Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
title_full Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
title_fullStr Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
title_full_unstemmed Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
title_short Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
title_sort methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: case report
topic 4200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626305/
https://www.ncbi.nlm.nih.gov/pubmed/28953662
http://dx.doi.org/10.1097/MD.0000000000008159
work_keys_str_mv AT abramaviciussilvijus methimazoleinducedliverinjuryovershadowedbymethylprednisolonepulsetherapycasereport
AT velickienedzilda methimazoleinducedliverinjuryovershadowedbymethylprednisolonepulsetherapycasereport
AT kaduseviciusedmundas methimazoleinducedliverinjuryovershadowedbymethylprednisolonepulsetherapycasereport